Fresenius Medical Care AG & Co. KGaA (FMS) Expected to Announce Quarterly Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.67 per share and revenue of $4.7963 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 6:00 AM ET.

Fresenius Medical Care AG & Co. KGaA Trading Up 1.2%

Shares of FMS stock opened at $24.40 on Monday. The company has a market capitalization of $14.15 billion, a PE ratio of 17.81, a price-to-earnings-growth ratio of 0.77 and a beta of 0.90. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $20.94 and a 52-week high of $30.46. The business’s fifty day moving average is $23.32 and its 200 day moving average is $24.47. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in FMS. AQR Capital Management LLC boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 14.2% in the 1st quarter. AQR Capital Management LLC now owns 14,297 shares of the company’s stock valued at $356,000 after purchasing an additional 1,777 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Fresenius Medical Care AG & Co. KGaA by 160.3% in the second quarter. JPMorgan Chase & Co. now owns 37,610 shares of the company’s stock worth $1,075,000 after purchasing an additional 23,163 shares during the last quarter. American Century Companies Inc. boosted its position in Fresenius Medical Care AG & Co. KGaA by 21.3% during the second quarter. American Century Companies Inc. now owns 29,173 shares of the company’s stock valued at $833,000 after buying an additional 5,127 shares during the period. Russell Investments Group Ltd. boosted its position in Fresenius Medical Care AG & Co. KGaA by 21.3% during the second quarter. Russell Investments Group Ltd. now owns 5,096 shares of the company’s stock valued at $146,000 after buying an additional 896 shares during the period. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 141.8% during the second quarter. EverSource Wealth Advisors LLC now owns 2,906 shares of the company’s stock valued at $83,000 after buying an additional 1,704 shares during the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on FMS shares. Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. The Goldman Sachs Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, January 5th. Wall Street Zen raised shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Finally, Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. Five analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.